Population-based cohort study finds no association between semaglutide treatment and liver disease outcomes, suggesting limited benefit for patients.
In this real-world study, semaglutide treatment was not associated with a reduced risk of liver cirrhosis or hepatocellular carcinoma among adults with type 2 diabetes mellitus.
No takes yet. Share an insight, caveat, or question.
Issachar et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: